Revvity aims to accelerate breakthroughs in cancer research

Revvity is positioning its technologies as a connected engine for discovery

GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy

Oxford-ZEISS advances breakthrough live-cell imaging platform for next-gen drug discovery

The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners

Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development

A major push to sharpen the future of cancer treatment is underway

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

AbbVie Phase 2 data show 62% response rate in ovarian cancer combo trial

Highlights Mirvetuximab-based regimen promise